Published in J Exp Med on August 16, 1999
Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med (2004) 2.05
Aberrant host defense against Leishmania major in the absence of SLPI. J Leukoc Biol (2014) 1.41
Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis (2002) 1.36
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol (2008) 1.32
Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med (2003) 1.30
Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun (2004) 1.20
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A (2003) 1.19
Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen (2011) 1.05
Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12). PLoS One (2012) 0.99
Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis. Arthritis Res Ther (2004) 0.94
Collagen biomarkers for arthritis applications. Biomark Insights (2007) 0.93
The mouth: a gateway or a trap for HIV? AIDS (2010) 0.93
Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol (2011) 0.93
Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages. Clin Exp Immunol (2000) 0.90
Arginine-specific gingipains from Porphyromonas gingivalis deprive protective functions of secretory leucocyte protease inhibitor in periodontal tissue. Clin Exp Immunol (2006) 0.88
Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain (2010) 0.88
The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol (2007) 0.88
The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps. J Leukoc Biol (2015) 0.88
Modulation of granulocyte-endothelium interactions by antileukoproteinase: inhibition of anti-type II collagen antibody-induced leukocyte attachment to the synovial endothelium. Arthritis Res Ther (2006) 0.87
Induction of macrophage-derived SLPI by Mycobacterium tuberculosis depends on TLR2 but not MyD88. Immunology (2005) 0.87
Potential prognostic, diagnostic and therapeutic markers for human gastric cancer. World J Gastroenterol (2014) 0.82
Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex. Respir Res (2008) 0.81
Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study. Arthritis Res Ther (2009) 0.81
Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis (2001) 0.81
Secretory leukocyte protease inhibitor is an inducible antimicrobial peptide expressed in Staphylococcus aureus endophthalmitis. Mediators Inflamm (2007) 0.80
Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4(+) lymphocyte proliferation. Immunology (2011) 0.79
Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene (2016) 0.78
The impact of IFN-γ receptor on SLPI expression in active tuberculosis: association with disease severity. Am J Pathol (2014) 0.77
Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1β, and NF-κB activators' expression in pristane-induced arthritis. Physiol Genomics (2013) 0.77
Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy. J Oral Pathol Med (2012) 0.77
Secretory Leukoprotease Inhibitor: A Native Antimicrobial Protein in the Innate Immune Response in a Rat Model of S. aureus Keratitis. J Ophthalmol (2009) 0.75
Gene expression profile in rat small intestinal allografts after cold preservation/reperfusion. World J Gastroenterol (2005) 0.75
Characterization of the ovine ortholog of secretory leukoprotease inhibitor. Mamm Genome (2005) 0.75
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Tissue destruction by neutrophils. N Engl J Med (1989) 13.81
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 2.95
Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. J Clin Invest (1987) 2.93
Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell (1997) 2.64
Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments. J Biol Chem (1980) 2.53
Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A (1986) 2.49
Antibacterial activity of antileukoprotease. Infect Immun (1996) 2.48
Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 2.41
A sensitive new substrate for chymotrypsin. Anal Biochem (1979) 2.35
Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol (1994) 2.02
Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest (1997) 1.67
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem (1990) 1.67
Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol (1989) 1.67
Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem (1989) 1.51
The possible role of neutrophil proteinases in damage to articular cartilage. Agents Actions (1978) 1.48
Elastase of U-937 monocytelike cells. Comparisons with elastases derived from human monocytes and neutrophils and murine macrophagelike cells. J Clin Invest (1982) 1.41
Cytotoxic T lymphocyte mediated cytolysis. Biochemistry (1988) 1.36
Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol (1999) 1.23
The extracellular matrix of cartilage in the growth plate before and during calcification: changes in composition and degradation of type II collagen. Calcif Tissue Int (1992) 1.21
Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun (1998) 1.16
Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. J Immunol (1998) 1.10
Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe Seyler (1988) 1.08
Cleavage of native type I collagen by human neutrophil elastase. Biochem J (1998) 1.08
L-Pyroglutamyl-L-prolyl-L-valine-p-nitroanilide, a highly specific substrate for granulocyte elastase. Scand J Clin Lab Invest (1983) 1.05
Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest (1998) 1.03
Cartilage degradation by polymorphonuclear leucocytes: in vitro assessment of the pathogenic mechanisms. Ann Rheum Dis (1993) 1.00
Proteinase-mediated cartilage degradation in osteoarthritis. Semin Arthritis Rheum (1991) 0.99
Primary structure and function of stromelysin/transin in cartilage matrix turnover. Matrix Suppl (1992) 0.95
The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. Biochem Biophys Res Commun (1997) 0.92
Secretory leucocyte proteinase inhibitor is produced by human articular cartilage chondrocytes and intervertebral disc fibrochondrocytes. Eur J Biochem (1993) 0.89
Distribution of the secretory leucocyte proteinase inhibitor in human articular cartilage. Biol Chem (1997) 0.87
Hemoglobin protects from streptococcal cell wall-induced arthritis. Arthritis Rheum (1999) 0.87
The action of trypsin on synthetic chromogenic arginine substrates. J Biochem (1979) 0.84
The serine-protease inhibitor of cartilage matrix is not a chondrocytic gene product. Eur J Biochem (1992) 0.83
Purification of a serine-proteinase inhibitor from human articular cartilage. Identity with the acid-stable proteinase inhibitor of mucous secretions. Biochem J (1991) 0.81
The rôle of proteases and antiproteases in bronchial secretions. Eur J Respir Dis Suppl (1987) 0.79
Inhibitors of human neutrophil cathepsin G: structural and biochemical studies. Arch Biochem Biophys (1992) 0.78
A comparative study of the low-molecular mass serine proteinase inhibitors of human connective tissues. Biol Chem Hoppe Seyler (1992) 0.78
Inhibition of cartilage degradation in rat collagen-induced arthritis but not adjuvant arthritis by the neutrophil elastase inhibitor MDL 101,146. Inflamm Res (1997) 0.78
Apparatus for Collecting and Measuring the Gases evolved during Fermentation. Biochem J (1911) 157.76
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med (2000) 11.12
Structure and ligand of a histone acetyltransferase bromodomain. Nature (1999) 10.08
N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A (1975) 9.24
Sequence and characteristics of IS900, an insertion element identified in a human Crohn's disease isolate of Mycobacterium paratuberculosis. Nucleic Acids Res (1989) 6.92
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 6.40
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol (1999) 5.58
Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA (1998) 5.09
Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet (1993) 5.09
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics (2001) 4.26
An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenet Genome Res (2004) 4.16
The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. J Exp Med (1970) 4.09
Macrophages as a source of HIV during opportunistic infections. Science (1997) 3.92
The PH domain: a common piece in the structural patchwork of signalling proteins. Trends Biochem Sci (1993) 3.89
Phosphoenolpyruvate and 2-phosphoglycerate: endogenous energy source(s) for sugar accumulation by starved cells of Streptococcus lactis. J Bacteriol (1977) 3.73
A case of cholera in Texas, 1973. Am J Epidemiol (1974) 3.71
Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet (1992) 3.58
Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med (1998) 3.56
Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol (1984) 3.36
Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest (1994) 3.30
The use of DNA probes identifying restriction-fragment-length polymorphisms to examine the Mycobacterium avium complex. Mol Microbiol (1987) 3.23
Molecular interactions between Anopheles stephensi midgut cells and Plasmodium berghei: the time bomb theory of ookinete invasion of mosquitoes. EMBO J (2000) 3.22
TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity (2001) 3.20
Structure and acetyl-lysine recognition of the bromodomain. Oncogene (2007) 3.20
Lymphocyte-mediated activation of fibroblast proliferation and collagen production. J Immunol (1978) 3.16
Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res (1981) 3.12
Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures. Biomaterials (1992) 3.10
Collagenase production by endotoxin-activated macrophages. Proc Natl Acad Sci U S A (1974) 3.05
Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med (1992) 3.03
Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism. J Clin Invest (1991) 3.00
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother (1994) 2.99
Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med (1993) 2.98
Induction of human IgE synthesis in B cells by mast cells and basophils. Nature (1993) 2.97
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 2.95
DNA probes demonstrate a single highly conserved strain of Mycobacterium avium infecting AIDS patients. Lancet (1989) 2.91
Lysolecithin and cell fusion. Nature (1970) 2.90
Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest (2001) 2.90
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J (1996) 2.89
Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int (2007) 2.87
Innovation in general practice: is the gap between training and non-training practices getting wider? Br J Gen Pract (1995) 2.74
A central role for P48/45 in malaria parasite male gamete fertility. Cell (2001) 2.73
A locus for febrile seizures (FEB3) maps to chromosome 2q23-24. Ann Neurol (1999) 2.73
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation (1999) 2.73
Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol (2009) 2.71
Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol (1995) 2.69
Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest (1995) 2.67
Epidemiology of bacterial endocarditis in The Netherlands. I. Patient characteristics. Arch Intern Med (1992) 2.67
Collagenase production by lymphokine-activated macrophages. Science (1975) 2.64
Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc (1999) 2.63
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol (2001) 2.59
stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol (1998) 2.58
Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today (1989) 2.56
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
The British Ophthalmological Surveillance Unit: an evaluation of the first 3 years. Eye (Lond) (2003) 2.50
Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med (2000) 2.48
In vivo regulation of glycolysis and characterization of sugar: phosphotransferase systems in Streptococcus lactis. J Bacteriol (1978) 2.42
Embryonic erythroid differentiation in the human leukemic cell line K562. Proc Natl Acad Sci U S A (1981) 2.42
Differentiating between audit and research: postal survey of health authorities' views. BMJ (1999) 2.41
Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 2.41
Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J Biol Chem (1985) 2.39
Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol (1979) 2.39
Lipopolysaccharide, tumor necrosis factor-alpha, and IL-1 beta prevent programmed cell death (apoptosis) in human peripheral blood monocytes. J Immunol (1991) 2.39
Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem (1999) 2.38
Role of a peptidase in phagocyte chemotaxis. Proc Natl Acad Sci U S A (1976) 2.38
Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization. J Cell Biol (1999) 2.36
Regulation of methyl-beta-d-thiogalactopyranoside-6-phosphate accumulation in Streptococcus lactis by exclusion and expulsion mechanisms. J Bacteriol (1981) 2.36
Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol (2000) 2.34
Characteristics and energy requirements of an alpha-aminoisobutyric acid transport system in Streptococcus lactis. J Bacteriol (1976) 2.32
Proteoglycans from bovine nasal cartilage. Properties of a soluble form of link protein. J Biol Chem (1979) 2.32
The in-training examination in internal medicine. Ann Intern Med (1994) 2.23
Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol (1991) 2.23
Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest (1989) 2.20
The phosphoenolpyruvate:sugar phosphotransferase system in gram-positive bacteria: properties, mechanism, and regulation. Crit Rev Microbiol (1988) 2.19
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J Exp Med (1990) 2.19
Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum (1987) 2.19
Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest (1991) 2.18
Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15
Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis (1997) 2.12
Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta. J Clin Invest (1991) 2.11
Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest (1984) 2.10
Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest (1992) 2.10
Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem (1999) 2.05
A microbiological comparison between acute and complicated appendicitis. Clin Infect Dis (1992) 2.02
Functions of Na+ and K+ in the active transport of -aminoisobutyric acid in a marine pseudomonad. J Biol Chem (1971) 2.02
Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia (2000) 2.02
The effect of glucocorticosteroids on the proliferation and kinetics of promonocytes and monocytes of the bone marrow. J Exp Med (1973) 2.01
Immune dysregulation in TGF-beta 1-deficient mice. J Immunol (1994) 2.00
Nutrition and metabolism of marine bacteria. XVII. Ion-dependent retention of alpha-aminoisobutyric acid and its relation to Na+ dependent transport in a marine pseudomonad. J Biol Chem (1969) 2.00